KM Management spol. s r.o.

The trials here

What the 27 trials at this site are about, from their registry records.

Conditions

• Crohn's disease15 trials
• Ulcerative colitis14 trials

Phase

• Phase 318 trials
• Phase 28 trials
• Phase 2/31 trial

Status

• Completed11 trials
• Active, not recruiting8 trials
• Recruiting8 trials

Lead sponsor

• AbbVie6 trials
• Abivax S.A.3 trials
• Hoffmann-La Roche3 trials
• Janssen Research & Development, LLC2 trials
• Merck Sharp & Dohme LLC2 trials
• and 10 more

Running trials

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)

  2024-518296-56-00· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

  NCT06880744· Phase 3· AbbVie· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819891· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis

  NCT06636656· Phase 2· Boehringer Ingelheim· Source

  Contact: Boehringer Ingelheim

• Recruiting

  Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

  NCT06456593· Phase 2· Abivax S.A.· Source

• Recruiting

  Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  NCT06548542· Phase 2· AbbVie· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  NCT06430801· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients

  NCT06408935· Phase 3· Janssen-Cilag Ltd.· Source

• Active, not recruiting

  ABTECT - Maintenance

  NCT05535946· Phase 3· Abivax S.A.· Source

• Recruiting

  A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

  NCT05287126· Phase 2· Pfizer· Source

• Active, not recruiting

  Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

  NCT04524611· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

  NCT03398135· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

  NCT03105102· Phase 3· AbbVie· Source

• Active, not recruiting

  A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

  NCT03345823· Phase 3· AbbVie· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease5 recruiting
• Ulcerative colitis3 recruiting

Closed trials

• Recruiting

  A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

  NCT07470879· Phase 2· Pfizer· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06588855· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  Phase IIa Study Evaluating AZD7798 in Crohn's Disease

  NCT06450197· Phase 2· AstraZeneca· Source

• Completed

  A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with active mild to moderate ulcerative colitis for the induction of remission.

  NCT06176560· Phase 3· Faes Farma S.A.· Source

• Active, not recruiting

  Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease

  NCT05910528· Phase 2· Hoffmann-La Roche· Source

• Completed

  A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05767021· Phase 3· Eli Lilly and Company· Source

• Completed

  ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

  NCT05507216· Phase 3· Abivax S.A.· Source

• Active, not recruiting

  Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

  NCT05588843· Phase 2· Sanofi· Source

• Completed

  A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease

  2024-513569-38-00· Phase 2/3· Arena Pharmaceuticals Inc.· Source

• Completed

  A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

  NCT03283085· Phase 3· Shire· Source

• Completed

  A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

  NCT02620046· Phase 3· Takeda· Source